证券代码：300158 证券简称：振东制药 公告编号：2025-044 山西振东制药股份有限公司 一、董事会会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 四次会议于 2025 年 8 月 22 日上午 9:00 在公司会议室通过现场及通 讯表决方式召开，会议通知于 2025 年 8 月 12 日以电话、邮件等方式 通知全体董事。会议应出席董事 9 名，实际出席董事 9 名。会议由公 司董事长李昆先生主持，公司全体监事及高级管理人员列席了会议。 本次会议的出席人数、召集、召开程序和议事内容均符合国家有关法 律、法规及《公司章程》的规定。 二、董事会会议审议情况 年半年度报告>及其摘要》。 《2025 年半年度报告》及《2025 年半年度报告摘要》内容详见 中国证监会创业板指定信息披露网站。 本议案已由董事会审计委员会审议并通过。 及其子公司使用自有资金进行现金管理的议案》。 本着股东利益最大化原则，为提高资金的使用效率，在确保不影 响公司正常经营以及保证流动性和资金安全的前提下，公司董事会同 意公司及公司子公司使用额度不超过人民币 10 亿元的自有资金进行 现金管理，并授权管理层在上 ...

Group 1 - The sixth meeting of the supervisory board of Shanxi Zhendong Pharmaceutical Co., Ltd. was held on August 22, 2025, with all three supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board reviewed the 2025 semi-annual report and found that the report accurately reflects the company's actual situation without any false statements or omissions [1] - The semi-annual report and its summary are available on the designated information disclosure website of the China Securities Regulatory Commission [1] Group 2 - The supervisory board approved the proposal for the company and its subsidiaries to use up to RMB 1 billion of idle self-owned funds for cash management, focusing on low to medium-risk financial products [2] - The decision to utilize idle funds is aimed at improving capital efficiency and cash management returns, aligning with the interests of the company and all shareholders, particularly minority shareholders [2] - The cash management proposal complies with relevant regulations and does not involve high-risk investment products as defined by the Shenzhen Stock Exchange [2]

Core Insights - The company reported a net profit of 7.93 million yuan for the first half of 2025, with a year-on-year growth of 73.42% in net profit excluding non-recurring items, driven by strategic adjustments, product pipeline expansion, and business structure optimization [1] Group 1: Strategic Focus and Resource Allocation - The company's strategic focus on innovative drugs and core areas has led to more efficient resource allocation, concentrating R&D and marketing resources on advantageous sectors [2] - The company has optimized its asset structure by shutting down loss-making enterprises and reducing low-margin businesses, which has effectively decreased losses and improved revenue quality [2] Group 2: Product Performance and Market Position - The core product matrix has contributed to stable revenue, with the star product, Dafeixin Minoxidil Solution, leading the market in hair loss treatment with a market share of 43% in the first half of 2025 [2] - New products, such as Shengbai Granules, have been included in multiple authoritative guidelines and have completed listings in 28 provinces, providing significant sales growth momentum [2] Group 3: Marketing Innovations - The company has employed innovative marketing strategies through chain pharmacies, e-commerce, and exclusive member operations, enhancing brand presence and product sales [3] Group 4: Innovation in Drug Pipeline - The company continues to expand its innovative drug pipeline, focusing on areas such as oncology, dermatology, and gynecology, with several drugs in development [4] - A significant breakthrough has been achieved with a vaginal probiotic capsule, which has shown superior efficacy and safety in clinical trials compared to traditional treatments [4][5] Group 5: Women's Health Ecosystem - The company is transitioning from a single product supplier to a comprehensive women's health solution provider, covering various health scenarios throughout women's life cycles [6] - A clinical network has been established, covering 3,000 tertiary hospitals and 5,000 maternal and child health hospitals, enhancing service delivery and user engagement [7] Group 6: Competitive Advantage and Future Outlook - The company's focus on women's health and innovative drug development is expected to enhance its market share and drive future growth [7] - The strategic alignment of innovation, market focus, and resource optimization positions the company to navigate industry transformations effectively [7]

Major Events - China Railway announced an investigation into the construction accident at the Qianzhai Yellow River Bridge, which resulted in 12 fatalities and 4 missing persons. The bridge is 1596.2 meters long with a contract value of approximately 436 million yuan. The company stated that this incident will not have a significant impact on its operations and performance [4] - Greenme announced plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [5] - Jingwang Electronics plans to invest 5 billion yuan in the Zhuhai Jinwan base expansion project, focusing on high-growth areas such as AI computing power and automotive intelligence [6][7] - Mingtai Aluminum intends to sell a 2.5% stake in Sanmenxia Aluminum to Jiaozuo Wanfang, with the share price set at 5.39 yuan per share, expecting to receive 149 million shares [8] - Dingsheng New Materials also plans to sell a 0.57% stake in Sanmenxia Aluminum under similar terms [9] Performance Overview - Xiyu Co. reported a net profit of 1.062 billion yuan for the first half of 2025, a year-on-year increase of 32.76%, with total revenue of 21.093 billion yuan, up 12.35% [10] - Jintailang reported a net profit of 358 million yuan, a 3.95% increase, with revenue of 9.528 billion yuan, up 2.49% [11] - Huaxia Eye Hospital achieved a net profit of 282 million yuan, a 6.2% increase, with revenue of 2.139 billion yuan, up 4.31% [12] - Juxin Technology reported a net profit growth of 123.19%, reaching 91.375 million yuan, with revenue of 449 million yuan, up 60.12% [13][14] - Zhendong Pharmaceutical reported a net profit of 7.9313 million yuan, a decline of 74.13%, with revenue of 1.457 billion yuan, down 3.3% [15] - China Merchants South Oil reported a net profit decline of 53.28%, totaling 570 million yuan, with revenue of 2.772 billion yuan, down 21.43% [16] - Chongqing Construction reported a net loss of 249 million yuan, with revenue of 14.359 billion yuan, down 7.97% [17] - Huacan Optoelectronics reported a net loss of 115 million yuan, with revenue of 2.532 billion yuan, up 33.93% [18] - Digital Government reported a net loss of 18.6927 million yuan, with revenue of 321 million yuan, down 40.34% [19] Major Contracts - Zhonggong International signed a contract for an overseas road engineering project in Nicaragua, valued at approximately 513 million yuan, which represents 4.2% of the company's total revenue for 2024 [20] Shareholding Changes - Tiancheng Technology announced that shareholder Qingxun Electronics plans to reduce its stake by up to 119,000 shares, representing no more than 0.1% of the total share capital [22] - Ailong Technology's controlling shareholder plans to reduce its stake by up to 1.69% through various trading methods [23]

Core Viewpoint - The company has reported a significant improvement in its financial performance, with a net profit of 7.93 million yuan and a 73.42% year-on-year increase in net profit attributable to the parent company, driven by strategic adjustments, product pipeline expansion, and business structure optimization [1] Group 1: Strategic Focus and Resource Allocation - The company's strategic focus on innovative drugs and core areas has led to more efficient resource allocation, concentrating R&D and marketing resources on advantageous sectors [2] - The company has optimized its asset structure by shutting down loss-making enterprises and reducing low-margin businesses, which has effectively decreased losses and improved revenue quality [2] Group 2: Product Performance and Market Position - The core product matrix has contributed to stable revenue, with the star product, Dafeixin Minoxidil Solution, leading the market in hair loss treatment with a 43% market share in the first half of 2025 [2] - New product launches, such as Shengbai Granules, have enriched the product pipeline and provided significant sales growth, having completed listings in 28 provinces [2][3] Group 3: Marketing Innovations - The company has employed innovative marketing strategies through various channels, including chain pharmacies and e-commerce, enhancing brand visibility and product sales [3] Group 4: Innovation in Drug Pipeline - The company continues to expand its innovative drug pipeline, focusing on multiple therapeutic areas, including oncology and dermatology, with several drugs in development [4] - A significant breakthrough has been achieved with a vaginal probiotic capsule, which has shown promising results in clinical trials, enhancing the company's innovative drug portfolio [4][5] Group 5: Women's Health Ecosystem - The company is transitioning from a single product supplier to a comprehensive women's health solution provider, covering various health scenarios and aiming for full lifecycle health management [6] - Strategic partnerships with major health platforms and a clinical network have been established to enhance service delivery and user engagement [7] Group 6: Competitive Advantage and Future Outlook - The company's focus on women's health, combined with innovation and strategic channel development, is expected to enhance its market share and drive future growth [7]

Core Viewpoint - The company reported a significant improvement in its financial performance for the first half of 2025, with a net profit of 7.93 million yuan and a 73.42% year-on-year increase in net profit attributable to the parent company, driven by strategic adjustments, product pipeline expansion, and enhanced sales of new products [1] Group 1: Strategic Focus and Financial Performance - The improvement in performance is attributed to a collaborative effort among strategy, products, and channels [1] - The company is focusing on core areas such as innovative drugs and skin care, concentrating R&D and marketing resources on advantageous sectors [1] - The optimization of asset structure includes shutting down loss-making enterprises and reducing low-margin businesses, which enhances revenue quality [1] Group 2: Product Development and Market Position - The core product matrix has contributed stable revenue, while new products have generated additional growth [1] - The star product, Dafeixin Minoxidil Solution, achieved a 43% market share in the hair loss treatment sector in the first half of 2025, complemented by the new hair growth tablets [1] - The 2024 launched Bai Granules, classified as a Category B traditional Chinese medicine, has been included in multiple authoritative guidelines and has completed listings in 28 provinces, aiding sales growth [1] Group 3: Marketing and Innovation - Innovative marketing strategies have activated growth momentum, utilizing chain pharmacies, e-commerce, and exclusive member operations to enhance brand visibility and product sales [2] - The company continues to expand its product pipeline and improve R&D efficiency, focusing on areas such as oncology, dermatology, and gynecology with several innovative drugs under development [2] Group 4: Clinical Trials and Product Launches - The company’s associate, Guangdong Longchuang Pharmaceutical, has achieved primary endpoints in the Phase III clinical trial of a vaginal probiotic capsule, adding significant value to its innovative drug portfolio [3] - This probiotic formulation offers a natural therapy approach to restore vaginal microbiota balance, showing higher cure rates and better safety compared to traditional antibiotics [3] - The product's Pre-NDA application has been accepted by the CDE, accelerating its market entry and positioning it as a benchmark product in women's reproductive health [3] Group 5: Competitive Advantage and Industry Positioning - The company has established a unique development pattern through strategic focus, innovative breakthroughs, and deep market engagement [3] - The approach of seeking development through innovation and building barriers through segmentation may become its core competitive advantage in navigating industry cycles [3]

新京报贝壳财经讯 振东制药8月24日晚间披露2025年半年报，上半年实现营业收入14.57亿元，同比下降 3.3%；归母净利润793.13万元，同比下降74.13%；基本每股收益0.0077元。 ...

人民财讯8月24日电，振东制药（300158）8月24日晚间披露2025年半年报，上半年实现营业收入14.57 亿元，同比下降3.3%；归母净利润793.13万元，同比下降74.13%；基本每股收益0.0077元。 ...

Core Viewpoint - Shanxi Zhendong Pharmaceutical Co., Ltd. has announced the use of its own funds for cash management, with a maximum investment of RMB 1 billion, aimed at improving fund utilization efficiency while ensuring normal operations and liquidity [1][2]. Group 1: Cash Management Details - The purpose of the investment is to enhance fund utilization efficiency without affecting normal operations and ensuring fund safety [2]. - The company plans to invest in low to medium-risk financial products issued by banks, securities firms, trust companies, and asset management companies, excluding high-risk investment types [2]. - The resolution is valid for one year from the date of approval by the board [2]. - The management is authorized to implement the cash management within the specified limit [2]. Group 2: Risk Management Measures - The company will adhere to prudent investment principles, selecting low to medium-risk investment products, with the finance department monitoring progress and addressing risks promptly [3]. - The supervisory department will audit and supervise the use and custody of funds for investment products, estimating potential returns and losses [3]. - The supervisory board has the authority to oversee the use of funds and may hire professional institutions for auditing if necessary [3]. Group 3: Board and Supervisory Approval - The proposal received approval from both the board and the supervisory board, which deemed it beneficial for improving fund utilization efficiency and cash management returns, aligning with the interests of the company and all shareholders [3].

Core Insights - The company reported a total operating revenue of 1.457 billion yuan for the first half of 2025, representing a year-on-year decrease of 3.30% [1] - The net profit attributable to shareholders of the listed company was 7.9313 million yuan, showing a significant decline of 74.13% compared to the previous year [1] - The company recorded a net loss of 8.1764 million yuan after deducting non-recurring gains and losses [1] - Basic earnings per share were reported at 0.0077 yuan [1]